We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01657032
First Posted: August 3, 2012
Last Update Posted: April 1, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Medical University of Warsaw
  Purpose
Treatment diarrhea with Lactobacillus GG or smectite has proven efficacy. A randomized, double blind, placebo-control trial was performed to assess the effectiveness of both LGG and smectite in management of children with acute gastroenteritis (AGE).

Condition Intervention Phase
Diarrhea Dietary Supplement: Smectite Dietary Supplement: Placebo Dietary Supplement: Lactobacillus GG Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis: A Double Blind Randomized, Placebo- Controlled Trial

Resource links provided by NLM:


Further study details as provided by Medical University of Warsaw:

Primary Outcome Measures:
  • Duration of Diarrhea [ Time Frame: counted in days during 7days ]
    The primary outcome measure is duration of diarrhea (counted in days; from the first loose stool to the last one; end of diarrhea defined as last loose stool or at least 12hours without stool).


Secondary Outcome Measures:
  • Frequency of Loose Stools, [ Time Frame: number of loose stools during 7 days ]
    number of loose stools during 7 days

  • Consistency of Stools [ Time Frame: day 4-th ]

    consistency of stools using Bristool Stool Scale Form on day 4-th. (The Bristol stool scale form is a medical aid designed to classify the form of human faeces into seven categories.

    Type 1 Separate hard lumps, like nuts (hard to pass) Type 2 Sausage-shaped but lumpy Type 3 Like a sausage but with cracks on the surface Type 4 Like a sausage or snake, smooth and soft Type 5 Soft blobs with clear-cut edges Type 6 Fluffy pieces with ragged edges, a mushy stool Type 7 Watery, no solid pieces. Entirely liquid Types 1-2 indicate constipation, with 3 and 4 being the ideal stools (especially the latter), as they are easy to defecate while not containing any excess liquid, and 5, 6 and 7 tending towards diarrhoea.


  • Need for Antibiotic Therapy, [ Time Frame: yes/no, for 7days ]
    need for antibiotic therapy because of diarrhea

  • Vomiting [ Time Frame: yes/no, for 7days ]
    If the child vomiting after randomization (yes/no)

  • Vomiting [ Time Frame: how many times for 7days ]
    How many times the child was vomiting (during the study)

  • Diarrhea Recurrence [ Time Frame: 7 days ]
    If the was a diarrhea recurrence during 7days

  • Tolerance of Products [ Time Frame: 7days ]
    tolerance of products (whether the child took medicaments),

  • Need for Hospitalization [ Time Frame: 7 days ]
    If the child need to hospitalized

  • Need for Intravenous Therapy [ Time Frame: yes/no, for 7days ]
    need for intravenous rehydration therapy (yes/no)

  • Duration of Intravenous Therapy [ Time Frame: 7days ]
    need for intravenous rehydration therapy (how long if needed)


Enrollment: 88
Study Start Date: August 2010
Study Completion Date: October 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lactobacillus GG and Smectite

Children received:

  • LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and
  • smectite, dose 3 g, once daily orally until diarrhea stopped
Dietary Supplement: Smectite
Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
Other Name: Smecta
Dietary Supplement: Lactobacillus GG
All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
Other Name: Dicoflor 30
Placebo Comparator: Lactobacillus GG and Placebo

Children received:

  • LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and
  • placebo (glucose), dose 3 g, once daily orally until diarrhea stopped
Dietary Supplement: Placebo
Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
Other Name: glucose
Dietary Supplement: Lactobacillus GG
All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
Other Name: Dicoflor 30

Detailed Description:

ESPGHAN agreed to use probiotics, with proven efficacy, and smectite in treatment of AGE as an adjunct to standard rehydration therapy. Among probiotics Lactobacillus GG were found to be beneficial in meta-analyses. Treatment with LGG was associated with a significant reduction in diarrhea duration.

A recent review systematically evaluated the efficacy of smectite in treating acute infections diarrhea in infants and children.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   3 Months to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • children < 5 years old
  • diarrhea (defined as the passage of 3 or more loose or watery stools per day) for > 1 day but < 5 days
  • inform consent sing

Exclusion Criteria:

  • diarrhea < 1 or > 5 days,
  • a recent history of diarrhea indicated either by parents/guardian or hospital case notes,
  • underlying chronic gastrointestinal disease,
  • undernutrition (weight/height ratio below the 5th percentile),
  • systematic infection,
  • immune defects or immunosuppressive treatment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01657032


Locations
Poland
Department of Paediatrics, The Medical University of Warsaw
Warsaw, Poland, 01-183
Sponsors and Collaborators
Medical University of Warsaw
  More Information

Publications:
Responsible Party: Medical University of Warsaw
ClinicalTrials.gov Identifier: NCT01657032     History of Changes
Other Study ID Numbers: KB2010
First Submitted: July 5, 2012
First Posted: August 3, 2012
Results First Submitted: November 20, 2013
Results First Posted: April 1, 2014
Last Update Posted: April 1, 2014
Last Verified: January 2010

Keywords provided by Medical University of Warsaw:
diarrhea
probiotics
diosmectite

Additional relevant MeSH terms:
Diarrhea
Gastroenteritis
Signs and Symptoms, Digestive
Signs and Symptoms
Gastrointestinal Diseases
Digestive System Diseases